What is Atossa Therapeutics, Inc.'s earnings per share (EPS)?

Atossa Therapeutics, Inc. (ATOS) reported diluted earnings per share of -$4.04 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Atossa Therapeutics, Inc. (ATOS) Financials

ATOS

FY2025 annual

Net Income -$34.8M -36.3% YoY

EPS (Diluted) -$4.04 YoY not available

Free Cash Flow -$29.8M -41.5% YoY

Operating Cash Flow -$29.8M -41.5% YoY

Market Cap $23.4M as of Oct 3, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 0.9x on $26.8M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 7, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 7, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ATOS SEC filings page.

This page shows Atossa Therapeutics, Inc. (ATOS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ATOS FY2025 2026-10-03

Losses are widening as research spending rises, while shrinking assets and higher liabilities reduce the balance sheet’s cushion.

In FY2025, operating cash flow of -$29.8M nearly matched the net loss of $34.8M, continuing FY2024’s close relationship between accounting losses and cash use. The losses are therefore translating into cash consumption rather than being driven mainly by noncash charges.

R&D investment rose from $14.1M in FY2024 to $21.2M in FY2025. The operating loss widened at the same time, indicating the added development spending has not yet produced operating leverage.

Total assets fell to $47.6M in FY2025 from $76.4M in FY2024, leaving a smaller balance-sheet base against which spending is funded. Liabilities rose to $8.3M while the current ratio fell to 5.5x; reported liquidity equaled 16.7 months of annual operating outflow, but the balance-sheet cushion narrowed.

Financial Health Signals

Financial health score not available

Atossa Therapeutics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

2/6

Atossa Therapeutics, Inc. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

Atossa Therapeutics, Inc. reported a net loss of $34.8M while operations used $29.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$8.7M

YoY+3.8%

QoQ+11.9%

Atossa Therapeutics, Inc.'s EBITDA was -$8.7M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 3.8% from the same quarter a year earlier. Against the prior quarter it is up 11.9%.

Net Income

-$8.5M

YoY-0.8%

QoQ+11.5%

Atossa Therapeutics, Inc. reported -$8.5M in net income in Q2 2026. This represents a decrease of 0.8% from the same quarter a year earlier. Against the prior quarter it is up 11.5%.

EPS (Diluted)

-$0.95

QoQ+14.4%

Atossa Therapeutics, Inc. earned -$0.95 per diluted share (EPS) in Q2 2026. Against the prior quarter it is up 14.4%.

Revenue

Not reported for Q2 2026.

Cash & Balance Sheet

Free Cash Flow

-$9.6M

YoY-32.9%

QoQ-0.7%

Atossa Therapeutics, Inc. recorded an outflow of $9.6M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 32.9% from the same quarter a year earlier. Against the prior quarter it is down 0.7%.

Cash & Debt

$26.1M

YoY-54.9%

QoQ-17.7%

5Y CAGR-28.8%

10Y CAGR+36.2%

Atossa Therapeutics, Inc. held $26.1M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

10M

QoQ+15.9%

5Y CAGR-39.8%

10Y CAGR-12.9%

Atossa Therapeutics, Inc. had 10M shares outstanding in Q2 2026. Against the prior quarter it is up 15.9%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-31.6%

YoY-17.1pp

QoQ-0.2pp

Atossa Therapeutics, Inc.'s ROE was -31.6% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 17.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.2 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$4.9M

YoY-11.0%

QoQ+2.5%

Atossa Therapeutics, Inc. invested $4.9M in research and development in Q2 2026. This represents a decrease of 11.0% from the same quarter a year earlier. Against the prior quarter it is up 2.5%.

Capital Expenditures

Atossa Therapeutics, Inc. reported no capital expenditure in Q2 2026.

Share Buybacks

Not reported for Q2 2026.

ATOS Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ATOS quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$2K-95.6%	$40K-93.7%	$633K+31.3%	$482K+32022.8%	$2K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$132K	$0-100.0%	$346K+866.6%	$36K+592.2%	$5K
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$131K-425.5%	$40K-70.7%	$137K-67.1%	$416K+535.0%	-$96K
R&D Expenses	N/A	$21.2M+50.1%	$14.1M-18.6%	$17.3M+14.9%	$15.1M+63.8%	$9.2M+39.4%	$6.6M-0.6%	$6.6M+57.8%	$4.2M+80.8%	$2.3M+202.2%	$770K-67.3%	$2.4M+112.5%	$1.1M+0.5%	$1.1M-44.0%	$2.0M	N/A
SG&A Expenses	N/A	$16.0M+18.2%	$13.5M-3.8%	$14.0M+11.4%	$12.6M+11.5%	$11.3M+41.4%	$8.0M-24.7%	$10.6M+47.0%	$7.2M+48.7%	$4.9M-25.0%	$6.5M-26.8%	$8.8M+9.9%	$8.1M-5.9%	$8.6M+181.1%	$3.0M-4.0%	$3.2M
Operating Income	N/A	-$37.1M-34.5%	-$27.6M+12.0%	-$31.4M-13.3%	-$27.7M-34.9%	-$20.5M-40.5%	-$14.6M+15.4%	-$17.3M-51.0%	-$11.4M-49.5%	-$7.6M+4.0%	-$8.0M+37.5%	-$12.8M-4.8%	-$12.2M-12.9%	-$10.8M-112.8%	-$5.1M-47.8%	-$3.4M
EBITDA	N/A	-$37.1M-34.5%	-$27.6M+12.0%	-$31.4M-13.3%	-$27.7M-35.1%	-$20.5M-40.8%	-$14.6M+15.4%	-$17.2M-51.1%	-$11.4M-51.5%	-$7.5M+1.9%	-$7.7M+38.6%	-$12.5M-6.8%	-$11.7M-13.4%	-$10.3M-108.8%	-$4.9M-44.7%	-$3.4M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$16K+4280.3%	$360-97.0%	$12K-33.1%	$18K
Income Tax	N/A	$0	$0	$0	$0	$0	$0	$0	$0	$0	N/A	$0	$0	$0	$0	$0
Net Income	N/A	-$34.8M-36.3%	-$25.5M+15.3%	-$30.1M-11.6%	-$27.0M-30.8%	-$20.6M-15.6%	-$17.8M-3.4%	-$17.2M-51.2%	-$11.4M-40.4%	-$8.1M-27.5%	-$6.4M+59.6%	-$15.8M-7.5%	-$14.7M-35.9%	-$10.8M-112.3%	-$5.1M-47.6%	-$3.4M
EPS (Basic)	N/A	-$4.04-32.9%	-$3.04-1166.7%	-$0.24-14.3%	-$0.21-16.7%	-$0.18	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	—	-$4.04	-$3.04	-$0.24-14.3%	-$0.21	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	9M	8M	126M-0.4%	127M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
R&D Expenses	$4.9M-11.0%	$4.8M+15.0%	N/A	$5.4M+57.4%	$5.5M+54.9%	$4.2M+10.9%	N/A	$3.4M-23.6%
SG&A Expenses	$3.8M+7.3%	$5.1M+56.3%	N/A	$3.9M+30.5%	$3.5M-0.4%	$3.3M+0.8%	N/A	$3.0M-0.9%
Operating Income	-$8.7M+3.8%	-$9.9M-33.1%	N/A	-$9.3M-44.9%	-$9.0M-27.2%	-$7.4M-6.2%	N/A	-$6.4M+14.5%
EBITDA	-$8.7M+3.8%	-$9.9M-33.1%	N/A	-$9.2M-44.9%	-$9.0M-27.2%	-$7.4M-6.2%	N/A	-$6.4M+14.5%
Income Tax	$0	$0	N/A	$0	$0	$0	N/A	$0
Net Income	-$8.5M-0.8%	-$9.6M-42.7%	N/A	-$8.7M-20.2%	-$8.4M-39.2%	-$6.7M-14.3%	N/A	-$7.2M-16.1%
EPS (Basic)	-$0.95+3.1%	-$1.11-42.3%	-$3.86-7620.0%	-$0.07-16.7%	-$0.98-1860.0%	-$0.78-1460.0%	-$0.05+16.7%	-$0.06-20.0%
EPS (Diluted)	-$0.95	-$1.11	-$3.86	-$0.07-16.7%	-$0.98	-$0.78	-$0.05+16.7%	-$0.06-20.0%
Diluted Shares (Avg)	9M	9M	N/A	129M+2.7%	9M	9M	N/A	126M0.0%

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense.

ATOS Balance Sheet

ATOS quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$47.6M-37.7%	$76.4M-20.6%	$96.3M-22.1%	$123.5M-12.6%	$141.3M+229.8%	$42.8M+195.6%	$14.5M+23.6%	$11.7M+43.6%	$8.2M+97.0%	$4.1M-33.6%	$6.2M-46.9%	$11.8M-2.0%	$12.0M+75.9%	$6.8M+122.2%	$3.1M
Current Assets	$45.6M-38.7%	$74.5M-19.3%	$92.2M-22.0%	$118.2M-16.3%	$141.2M+230.2%	$42.8M+198.7%	$14.3M+24.0%	$11.5M+46.2%	$7.9M+142.7%	$3.3M-24.2%	$4.3M-54.0%	$9.3M+38.1%	$6.8M+239.9%	$2.0M-32.5%	$2.9M
Cash & Equivalents	$41.3M-41.9%	$71.1M-19.6%	$88.5M-20.2%	$110.9M-18.7%	$136.4M+244.8%	$39.6M+214.4%	$12.6M+21.2%	$10.4M+43.8%	$7.2M+138.4%	$3.0M-18.5%	$3.7M-56.3%	$8.5M+34.0%	$6.3M+267.6%	$1.7M-9.7%	$1.9M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$9K	$0	$0	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$298K+114.2%	$139K-1.8%	$142K+11474.0%	$1K
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$8.3M+66.2%	$5.0M-5.1%	$5.2M-6.0%	$5.6M+78.1%	$3.1M-80.1%	$15.7M+1074.9%	$1.3M-54.2%	$2.9M+137.9%	$1.2M+17.0%	$1.0M-58.1%	$2.5M+10.4%	$2.3M+61.0%	$1.4M-14.7%	$1.7M+9.2%	$1.5M
Current Liabilities	$8.3M+66.2%	$5.0M-5.1%	$5.2M-6.0%	$5.6M+78.1%	$3.1M-80.1%	$15.7M+1084.7%	$1.3M-54.6%	$2.9M+137.9%	$1.2M+17.0%	$1.0M-58.1%	$2.5M+10.5%	$2.3M+61.5%	$1.4M-15.1%	$1.7M+9.2%	$1.5M
Non-Current Liabilities	$0	$0	$0	$0	$0	$0-100.0%	$11K	$0	$0	$0	$0-100.0%	$2K-57.3%	$6K	$0	$0
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$49K+745.6%	$6K	N/A	N/A
Total Equity	$39.4M-44.9%	$71.5M-21.5%	$91.0M-22.8%	$118.0M-14.6%	$138.1M+408.5%	$27.2M+106.5%	$13.2M+49.4%	$8.8M+26.9%	$6.9M+124.0%	$3.1M-17.2%	$3.7M-60.6%	$9.5M-10.4%	$10.6M+104.8%	$5.2M+231.8%	$1.6M
Retained Earnings	-$246.6M-16.4%	-$211.8M-13.7%	-$186.3M-19.3%	-$156.2M-20.9%	-$129.2M-15.5%	-$111.9M-19.0%	-$94.1M-22.4%	-$76.8M-17.4%	-$65.4M-14.2%	-$57.3M-12.5%	-$50.9M-44.8%	-$35.2M-71.4%	-$20.5M-110.8%	-$9.7M-109.2%	-$4.7M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$32.3M-50.0%	$37.9M-46.4%	$47.6M-37.7%	$58.0M-27.0%	$64.5M-24.9%	$70.7M-22.3%	$76.4M-20.6%	$79.5M-21.8%
Current Assets	$31.0M-50.4%	$36.7M-46.7%	$45.6M-38.7%	$55.7M-27.8%	$62.5M-23.5%	$68.7M-21.0%	$74.5M-19.3%	$77.1M-21.0%
Cash & Equivalents	$26.1M-54.9%	$31.7M-51.3%	$41.3M-41.9%	$51.8M-30.7%	$57.9M-27.2%	$65.1M-22.4%	$71.1M-19.6%	$74.8M-20.5%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$5.5M-20.1%	$7.5M+37.5%	$8.3M+66.2%	$8.2M+41.9%	$6.8M+19.7%	$5.4M+1.8%	$5.0M-5.1%	$5.8M+68.3%
Current Liabilities	$5.5M-20.1%	$7.5M+37.5%	$8.3M+66.2%	$8.2M+41.9%	$6.8M+19.7%	$5.4M+1.8%	$5.0M-5.1%	$5.8M+68.3%
Non-Current Liabilities	$0	$0	$0	$0	$0	$0	$0	$0
Total Equity	$26.8M-53.5%	$30.5M-53.3%	$39.4M-44.9%	$49.8M-32.4%	$57.7M-28.0%	$65.3M-23.8%	$71.5M-21.5%	$73.7M-25.0%
Retained Earnings	-$264.6M-16.6%	-$256.2M-17.2%	-$246.6M-16.4%	-$235.6M-14.7%	-$226.9M-14.5%	-$218.5M-13.7%	-$211.8M-13.7%	-$205.4M-15.1%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

ATOS Cash Flow Statement

ATOS quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$35.8M	-$29.8M-41.5%	-$21.0M-0.4%	-$20.9M-0.9%	-$20.8M-26.0%	-$16.5M-42.4%	-$11.6M-26.7%	-$9.1M-1.9%	-$9.0M-35.9%	-$6.6M-22.7%	-$5.4M+61.5%	-$14.0M-32.2%	-$10.6M-19.5%	-$8.8M-126.4%	-$3.9M-11.7%	-$3.5M
Depreciation & Amortization	N/A	$16K-5.9%	$17K-26.1%	$23K+187.5%	$8K-65.2%	$23K-51.1%	$47K-11.0%	$53K+19.4%	$44K-65.7%	$129K-57.5%	$303K+11.3%	$273K-43.2%	$480K+1.6%	$473K+262.3%	$131K+735.6%	$16K
Stock-Based Compensation	N/A	$2.6M+15.4%	$2.3M-50.4%	$4.6M-31.9%	$6.8M+28.9%	$5.3M+74.5%	$3.0M-57.5%	$7.1M+574.1%	$1.1M+33.9%	$787K-10.2%	$876K+4.3%	$840K+51.0%	$556K-61.5%	$1.4M+1085.2%	$122K-13.0%	$140K
Capital Expenditures	$14K	$23K+21.1%	$19K+35.7%	$14K-48.1%	$27K+200.0%	$9K0.0%	$9K+18.0%	$8K-93.1%	$111K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	-$35.8M	-$29.8M-41.5%	-$21.0M-0.4%	-$21.0M-0.8%	-$20.8M-26.1%	-$16.5M-42.3%	-$11.6M-26.7%	-$9.1M-0.7%	-$9.1M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$14K	-$23K-21.1%	-$19K-35.7%	-$14K+99.7%	-$4.7M-52422.2%	-$9K0.0%	-$9K-18.0%	-$8K+93.1%	-$111K	N/A	-$9K+96.8%	-$288K+16.0%	-$343K	N/A	-$135K+1.7%	-$137K
Financing Cash Flow	$4.0M	$0-100.0%	$3.7M+349.0%	-$1.5M	$0-100.0%	$113.3M+193.9%	$38.6M+240.1%	$11.3M-7.8%	$12.3M+14.0%	$10.8M+129.6%	$4.7M	N/A	N/A	N/A	$3.8M-30.4%	$5.5M
Share Buybacks	N/A	N/A	$0-100.0%	$1.5M	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$9.6M-32.9%	-$9.6M-60.8%	-$10.5M-49.5%	-$6.0M-26.4%	-$7.3M-60.2%	-$6.0M-26.8%	-$7.1M-26.6%	-$4.8M-22.3%
Depreciation & Amortization	$4K0.0%	$4K0.0%	$4K0.0%	$4K0.0%	$4K0.0%	$4K-20.0%	$4K-71.4%	$4K+33.3%
Stock-Based Compensation	$815K+2.4%	$722K+28.2%	N/A	$784K+4.7%	$796K+126.1%	$563K+35.0%	N/A	$749K-19.1%
Capital Expenditures	$0	$0-100.0%	$7K	$7K-30.0%	$0-100.0%	$9K+50.0%	$0	$10K+900.0%
Free Cash Flow	-$9.6M-32.9%	-$9.6M-60.5%	-$10.5M-49.6%	-$6.0M-26.3%	-$7.3M-60.1%	-$6.0M-26.9%	-$7.1M-26.6%	-$4.8M-22.6%
Investing Cash Flow	$0	$0+100.0%	-$7K	-$7K+30.0%	$0+100.0%	-$9K-50.0%	$0	-$10K-900.0%
Financing Cash Flow	$4.0M	$0	$0-100.0%	$0	$0-100.0%	$0-100.0%	$3.4M	$0+100.0%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

ATOS Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ATOS quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-7431.9%	100.0%+78.3pp	21.7%-64.7pp	86.4%	-6379.3%
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-725746.2%	-30323.0%	-1704.9%	-1052.0%	-228612.7%
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-896491.6%	-36518.8%	-1704.9%	-1054.3%	-229484.5%
Return on Equity	-88.3%-52.7pp	-35.7%-2.6pp	-33.1%-10.2pp	-22.9%-7.9pp	-14.9%+50.7pp	-65.6%+65.4pp	-131.0%-1.5pp	-129.5%-12.5pp	-117.1%+88.6pp	-205.6%+215.6pp	-421.2%-266.9pp	-154.3%-52.6pp	-101.7%-3.6pp	-98.2%+122.5pp	-220.7%
Return on Assets	-73.0%-39.7pp	-33.4%-2.1pp	-31.3%-9.4pp	-21.8%-7.2pp	-14.6%+27.0pp	-41.6%+77.4pp	-119.0%-21.7pp	-97.3%+2.2pp	-99.5%+54.2pp	-153.7%+98.8pp	-252.4%-127.8pp	-124.6%-34.8pp	-89.8%-15.4pp	-74.4%+37.6pp	-112.1%
Current Ratio	5.53-9.5x	14.99-2.6x	17.61-3.6x	21.23-24.0x	45.18+42.5x	2.73-8.1x	10.83+6.9x	3.96-2.5x	6.45+3.3x	3.11+1.4x	1.72-2.4x	4.13-0.7x	4.82+3.6x	1.21-0.7x	1.95
Debt-to-Equity	0.21+0.1x	0.070.0x	0.060.0x	0.050.0x	0.02-0.6x	0.58+0.5x	0.10-0.2x	0.33+0.2x	0.18-0.2x	0.34-0.3x	0.67+0.7x	0.010.0x	0.00-0.3x	0.32-0.7x	0.97
Asset Turnover	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	0.000.0x	0.000.0x	0.050.0x	0.07+0.1x	0.00

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	-31.6%-17.1pp	-31.4%-21.2pp	N/A	-17.5%-7.6pp	-14.6%-7.0pp	-10.3%-3.4pp	N/A	-9.8%-3.5pp
Return on Assets	-26.3%-13.2pp	-25.3%-15.8pp	N/A	-15.0%-5.9pp	-13.1%-6.0pp	-9.5%-3.0pp	N/A	-9.1%-3.0pp
Current Ratio	5.69-3.5x	4.92-7.8x	5.53-9.5x	6.77-6.5x	9.17-5.2x	12.67-3.7x	14.99-2.6x	13.30-15.0x
Debt-to-Equity	0.20+0.1x	0.24+0.2x	0.21+0.1x	0.17+0.1x	0.120.0x	0.080.0x	0.070.0x	0.080.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Atossa Therapeutics, Inc. ATOS	FY2025	N/A	-$34.8M	N/A	$23.4M	—
Pyxis Oncology, Inc. PYXS	FY2025	$13.9M	-$79.6M	N/A	$178.5M	56/100
Adagene Inc. ADAG	FY2025	$7.7M	-$17.6M	N/A	$191.4M	63/100
Spero Therapeutics, Inc. SPRO	FY2025	$66.8M	$8.6M	12.8%	$69.3M	65/100
Alto Neuroscience Inc. ANRO	FY2025	N/A	-$63.2M	N/A	$973.2M	—
MacroGenics, Inc. MGNX	FY2025	$149.5M	-$75K	-0.1%	$228.0M	57/100

Where Atossa Therapeutics, Inc. Ranks

Frequently Asked Questions

Is Atossa Therapeutics, Inc. profitable?

No, Atossa Therapeutics, Inc. (ATOS) reported a net income of -$34.8M in fiscal year 2025.

What is Atossa Therapeutics, Inc.'s EBITDA?

Atossa Therapeutics, Inc. (ATOS) had EBITDA of -$37.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Atossa Therapeutics, Inc.'s return on equity (ROE)?

Atossa Therapeutics, Inc. (ATOS) has a return on equity of -88.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Atossa Therapeutics, Inc.'s free cash flow?

Atossa Therapeutics, Inc. (ATOS) recorded an outflow of $29.8M in free cash flow during fiscal year 2025. This represents a -41.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Atossa Therapeutics, Inc.'s operating cash flow?

Atossa Therapeutics, Inc. (ATOS) recorded an outflow of $29.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Atossa Therapeutics, Inc.'s total assets?

Atossa Therapeutics, Inc. (ATOS) had $47.6M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Atossa Therapeutics, Inc.'s capital expenditures?

Atossa Therapeutics, Inc. (ATOS) invested $23K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Atossa Therapeutics, Inc. spend on research and development?

Atossa Therapeutics, Inc. (ATOS) invested $21.2M in research and development during fiscal year 2025.

How many shares does Atossa Therapeutics, Inc. have outstanding?

Atossa Therapeutics, Inc. (ATOS) had 9M shares outstanding as of fiscal year 2025.

What is Atossa Therapeutics, Inc.'s current ratio?

Atossa Therapeutics, Inc. (ATOS) had a current ratio of 5.53 as of fiscal year 2025, which is generally considered healthy.

What is Atossa Therapeutics, Inc.'s debt-to-equity ratio?

Atossa Therapeutics, Inc. (ATOS) had a debt-to-equity ratio of 0.21 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Atossa Therapeutics, Inc.'s return on assets (ROA)?

Atossa Therapeutics, Inc. (ATOS) had a return on assets of -73.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Atossa Therapeutics, Inc.'s P/E ratio?

Atossa Therapeutics, Inc. (ATOS) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $23.4M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Atossa Therapeutics, Inc.'s price-to-sales ratio?

Atossa Therapeutics, Inc. (ATOS) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $23.4M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Atossa Therapeutics, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Atossa Therapeutics, Inc. (ATOS) held $41.3M in cash, cash equivalents and investments, and reported an operating cash outflow of $29.8M over that year. Dividing the one by the other, the reported balance equals about 17 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Atossa Therapeutics, Inc.'s Piotroski F-Score?

Atossa Therapeutics, Inc. (ATOS) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Atossa Therapeutics, Inc.'s earnings high quality?

Atossa Therapeutics, Inc. (ATOS) reported a net loss of $34.8M while operations used $29.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.